Does *Mycobacterium avium* subspecies *paratuberculosis* cause Crohn’s disease?

R Balfour Sartor

Reassessing this persistent theory in light of advances in molecular microbial detection and genetic pathogenesis of disease

**S**imilarities between chronic idiopathic granulomatous ileocolitis and mycobacterial infections have been noted since the original descriptions of the clinical syndrome now called Crohn’s disease.1–4 Interest in a possible infectious origin of this disorder was renewed in 1989 when Chiiodini *et al* cultured apparently identical *Mycobacterium avium* subspecies *paratuberculosis* (MAP) from three patients with Crohn’s disease.5 This controversy increased in intensity following the detection of the specific DNA insertion sequence, IS900, of MAP in relatively high numbers of patients with Crohn’s disease relative to ulcerative colitis and normal controls,6 and is now raging as several different groups have detected this organism in the food chain7 and water supply,8 proposed maternal-fetal transmission in human milk,9 reported long term responses to antimycobacterial antibiotic combinations,10 and even cultured viable *M paratuberculosis* in blood samples of Crohn’s disease patients.11

Additional data to support an association of MAP with Crohn’s disease is provided by Autschbach and colleagues12 in this issue of *Gut* (see page 944). This carefully performed and well controlled study used nested polymerase chain reaction (PCR) to detect the IS900 insertion element of MAP in 52% of Crohn’s disease resected tissues versus 2% of ulcerative colitis and 0% of mostly non-inflammatory control tissues. This study provides novel data regarding the prevalence of MAP in various phenotypes of Crohn’s disease by showing slightly higher detection of IS900 DNA in colonic (66.7%) compared with distal ileal (40.5%) tissues and decreased detection rates with corticosteroid use. In addition, these authors reported weak associations with perianal involvement and a shorter duration of disease but no correlation with patient sex, age at diagnosis, strictureting versus penetrating phenotype, or presence of granulomas.

Data from this study help address some of the controversies that have fuelled the vigorous debate between committed advocates and confirmed sceptics that is receiving increasing attention in the scientific literature, lay press, and internet chat rooms. The arguments in favour or opposed to this theory (table 1) have some merit but many are flawed by incomplete data and lack of rigorous reflection. There is no doubt that a potential source of zoonotic infection exists, with widespread MAP infections in the dairy herds of Europe, North America, and Australia,13,14 excretion of MAP in milk from infected cows,15 relative resistance of intracellular MAP to widely used pasteurisation techniques,16 and recovery of viable MAP from the water supplying Los Angeles.17 Moreover, the vast majority of studies using diverse techniques have detected MAP DNA or cultured this organism in higher frequency from tissues of patients with Crohn’s disease than from those with ulcerative colitis and other disorders, although the reported frequency of recovery in both Crohn’s disease and ulcerative colitis have ranged from 0% to 100%.17 These results are consistent with two possibilities: either MAP infection could cause Crohn’s disease in a subset of patients that are either selectively exposed to this organism or who are genetically susceptible to infection or, alternatively, this relatively common dietary organism may selectively colonise (or a dead organism selectively lodge in) the ulcerated mucosa of Crohn’s disease patients but not initiate or perpetuate intestinal inflammation. Molecular fingerprints show that genotypes of bovine and human isolates are not similar but instead indicate that human and ovine (sheep) strains are more closely related.18 Maternal/fetal transmission of MAP has been proposed following culture of MAP from breast milk of two patients with Crohn’s disease.9 However, the frequency of positive cultures in human milk is uncertain, this observation has not been replicated by other investigators, and there is no evidence of increased frequency of Crohn’s disease in the offspring of mothers versus fathers with Crohn’s disease. Even if transmission of viable MAP occurs, a plausible mechanism of tissue injury and induction of chronic intestinal inflammation has not been proposed. Even advocates of the theory that MAP causes Crohn’s disease concede that infection, if present, consists of a low bacterial load and that no histochomical evidence of acid fast staining in Crohn’s disease tissues is seen. This could be explained by a paucibacillary infection with an obligate intracellular, cell wall deficient bacterial form.19 In this setting, inflammation and tissue injury must be mediated by a cell mediated immune response. However, a cellular immune response to MAP has not been documented in Crohn’s disease patients,20 despite increased serological responses to MAP antigens in the same patients. Another serious flaw in the MAP pathogenesis of Crohn’s disease theory is the observation that these patients respond to chronic immunosuppressive therapies21 and acquired immunosuppressive infections decrease disease activity as CD4 T cell counts fall.22 In contrast, *M tuberculosis* massively proliferates with anti-tumour necrosis factor or steroid treatment and *M avium intracellular* thrives in the intestine as CD4 counts fall in human immunodeficiency virus infected patients. It is possible that intracellular cell wall deficient MAP may not replicate well despite immunosuppression, but this issue has never been studied by in vitro investigation or in animals with Johne’s disease. In the study by Autschbach *et al*, corticosteroid therapy was associated with lower MAP detection rates.12

The most irrefutable evidence that a microbial agent causes a disease is long term remission of clinical manifestations and an altered natural history of disease following clearance of the infection. In vitro sensitivity analyses show that clinical isolates of MAP are not responsive to traditional anti-*M tuberculosis* agents, and therefore lack of efficacy with isoniazid, ethambutol, and rifampicin treatment for two years with a three year follow up23 does not detract from this theory. However, reports of efficacy of combinations of clarithromycin or azithromycin, rifabutin, and a variety of other agents in 58–82% of Crohn’s disease patients24–26 are also not definitive due to the uncontrolled nature of these studies, the small number of patients treated, the variable treatment regimens, and the fact that these antibiotics, particularly clarithromycin,
have a broad spectrum of activity against commensal enteric bacteria. Moreover, these studies and a yet to be published ongoing controlled trial in Australia using these agents in Crohn’s disease patients are flawed by not assessing IS900 DNA in biopsy specimens by PCR and serological responses to MAP before and after therapy, so that clinical results can be correlated with the presence of tissue MAP and its clearance with treatment. Selective responses in those patients with detectable MAP colonisation that clear infection with antibiotic treatment would strongly imply a causal relationship of the infection.

Our evolving molecular understanding of gene-environmental interactions offers an opportunity to reassess the MAP causation theory of Crohn’s disease in a new light. NOD2/CARD15 is an intracellular receptor for muramyl dipeptide (MDP), the smallest immunologically active component of bacterial peptidoglycan. Ligation of MDP by NOD2/CARD15 activates nuclear factor κB. This pathway may contribute to clearance of intracellular bacterial infection and secretion of α defensins by Paneth cells, which constitutively express NOD2/CARD15. The three most common polymorphisms of this gene are found in 25–35% of Caucasian Crohn’s disease patients and lead to defective nuclear factor κB activation by MDP. Expression of the common truncation mutation of NOD2/CARD15 is associated with defective clearance of invasive salmonella infection in epithelial cells. In addition, NOD2/CARD15 mutations in Crohn’s disease are associated with diminished mucosal α defensin expression. Thus an attractive explanation linking NOD2/CARD15 to Crohn’s disease is that defective function of this gene results in ineffective clearance of intracellular MAP infection and in decreased luminal α defensin secretion that permits increased mucosal adherence and epithelial invasion of ingested organisms. Defective clearance of intracellular MAP by innate immune cells, including macrophages, could explain the seemingly paradoxical therapeutic response of some Crohn’s disease patients to granulocyte-macrophage colony stimulating factor. However, the phenotypic information provided by Autschbach and colleagues argues against an association of NOD2/CARD15 with MAP infection, as MAP was more commonly detected in colonic than ileal disease and was not more frequently found in early onset or strictureing disease. Likewise, patients with extensive ileocolitis responded better to macrolide antibiotics and rifabutin than did those with isolated ileal disease. These results directly contrast with the strong association of NOD2/CARD15 polymorphisms with early onset ileal Crohn’s disease with a strictureting phenotype.

Crohn’s disease certainly has environmental and host genetic influences that interact to cause clinically evident disease. It is equally clear that MAP is widely present in our food chain and that the DNA of this organism can be recovered from the intestine of Crohn’s disease patients. Although existing data do not compellingly implicate MAP as a causal agent in Crohn’s disease, neither do they definitively exclude this possibility. We must determine whether MAP infection causes human disease, which is unlikely in my opinion, or whether this environmental contaminant incidently lodges in ulcerated mucosa. Is MAP analogous to Helicobacter pylori in peptic ulcer disease, gastritis, and gastric cancer, where host genetics and microbial virulence factors determine immune responses that mediate clinical disease in a small minority of patients exposed to a widespread infectious agent? Are we repeating the mistake of H pylori where the scientific establishment resisted a new theory that challenged established paradigms of peptic ulcer disease until overwhelming clinical evidence made such resistance untenable? Well designed clinical, microbiological, and mechanistic experiments are urgently needed to definitively settle this still unresolved debate.

To establish a causal relationship between MAP and Crohn’s disease, we need to determine if clearance of MAP selectively changes the natural history of disease in an infected subset of patients, perform definitive investigations of cellular immune responses to this organism in Crohn’s disease and control patients, determine if NOD2/CARD15 and other microbial signalling pathways influence intracellular MAP infection and clearance, and review results of ongoing large multi-institutional studies to detect MAP in shared coded tissues by various molecular and culture methods. These studies need to be designed and conducted by established investigators who bring no predetermined biases to this contentious topic. If MAP is responsible for a subset of Crohn’s disease, public health measures must be implemented to eliminate the source of infection in our food chain and food processing practices must be modified. In addition, the medical community must develop ways to efficiently and cost effectively screen for MAP infection and development methods to efficiently clear this organism from infected tissues, possibly through a combination of effective antibiotics and immunostimulants that enhance innate clearance responses. If there is no evidence of a causal association of MAP and Crohn’s disease, we need to direct resources to other avenues of research. This controversy has persisted far too long and needs to be expeditiously resolved.

doi: 10.1136/gut.2004.058889

Correspondence to: Dr R Balfour Sartor, UNC Department of Medicine/Division of Gastroenterology and Hepatology, CB #7032, Room 7309 Biomolecular Bldg (MBRB), Chapel Hill, NC 27599-7032, USA; rbs@med.unc.edu
Conflict of interest: None declared.

REFERENCES


Table 1 Arguments for and against a Mycobacterium avium subspecies paratuberculosis (MAP) causation of Crohn’s disease

<table>
<thead>
<tr>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical and pathological similarities between Johne’s and Crohn’s diseases</td>
<td>Differences in clinical and pathological responses in Johne’s and Crohn’s diseases</td>
</tr>
<tr>
<td>Presence of food chain (milk, meat) and water supplies</td>
<td>Lack of epidemiological support of transmissible infection</td>
</tr>
<tr>
<td>Increased detection of MAP in Crohn’s disease tissues by culture, PCR, FISH</td>
<td>No evidence of transmission to humans in contact with infected MAP</td>
</tr>
<tr>
<td>Positive blood cultures of MAP in Crohn’s disease patients</td>
<td>Genotypes of Crohn’s disease and bovine MAP isolates not similar</td>
</tr>
<tr>
<td>Increased serological responses to MAP in Crohn’s disease patients</td>
<td>Variability in detection of MAP by PCR (0–100% in Crohn’s disease and ulcerative colitis tissues)</td>
</tr>
<tr>
<td>Detection of MAP in human breast milk by culture and PCR</td>
<td>No evidence of mycobacterial cell wall by histochemical staining</td>
</tr>
<tr>
<td>Progression of cervical lymphadenopathy to distal ileitis in a patient with MAP infection</td>
<td>No worsening of Crohn’s disease with immunosuppressive agents or HIV infection</td>
</tr>
<tr>
<td>Therapeutic responses to combination antimicrobial therapy that include macrolide antibiotics</td>
<td>No documented cell mediated immune responses to MAP in patients with Crohn’s disease</td>
</tr>
<tr>
<td>murky antioxidant responses to traditional antimycobacterial antibiotics</td>
<td>No therapeutic response to traditional antimycobacterial antibiotics</td>
</tr>
</tbody>
</table>

MAP, Mycobacterium avium subspecies paratuberculosis; PCR, polymerase chain reaction; FISH, fluorescent in situ hybridisation; HIV, human immunodeficiency virus.
Colitis

Probiotics and barrier function in colitis
P Gionchetti, K M Lammers, F Rizzello, M Campieri

Probiotic administration may exert a protective effect in colitis by preventing mucosal barrier disruption and influencing the extent of mucosal injury

There is strong evidence of a role for the indigenous flora in driving inflammatory responses in inflammatory bowel disease (IBD) in genetically predisposed individuals. For years, researchers have tried in vain to identify a specific pathogen as the cause of these chronic intestinal inflammatory disorders but the possibility that one or more bacterial agents are responsible cannot be ruled out. Considering the implications of a pathogen in IBD, as yet undiscovered due to technical limitations, it was hypothesised that modulation of an abnormal microflora in these patients by introducing high titres of “protective” bacteria might overwhelm the “aggressive” strain(s) and inhibit its deleterious effects. On this basis, probiotic treatment was proposed as a therapeutic approach.2

Probiotics are defined as “living organisms which, on ingestion in certain numbers, exert health benefits beyond inherent basic nutrition”.3 Bacteria associated with probiotic activity are most commonly lactobacilli, bifidobacteria, and streptococci but other non-pathogenic bacteria such as some strains of Escherichia coli and microorganisms such as the yeast Saccharomyces boulardii have been used in IBD.

Encouraging results have been obtained with probiotics in several experimental animal models of IBD.4-7 In humans, probiotics are effective in the prevention of pouchitis onset and relapse.8-11 Results in ulcerative colitis are promising, both in prevention of relapse and treatment of mild to moderate attacks.12-13 Results in Crohn’s disease are not yet clear because of conflicting data and the limited number of well performed studies.14-16 Efforts are being made by many researchers to unravel the precise mechanisms by which probiotic bacteria and their metabolic products (short chain fatty acids, vitamins) exert their...
beneficial effects. Several mechanisms have been proposed to account for probiotic action. These include: (a) antagonistic activity against pathogenic bacteria by competing for binding sites; (b) stimulation of mucosal defence at the level of both immune and epithelial function, by increasing sIgA production, decreasing proinflammatory and increasing anti-inflammatory cytokine levels, and inducing production of protective substances by the epithelium, such as antimicrobial peptides (bacteriocins) and hydrogen peroxide, mucins, and heat shock proteins; and (c) inhibition of bacterial translocation and reinforcement of barrier function by mechanisms that have yet to be established in detail.

The paper presented in this issue of *Gut* describes the effect of modulation of the microflora by *Lactobacillus casei* on disease course and extent in the trinitrobenzene sulphonic acid (TNBS) model of experimental colitis. The elegance of this study lies in the experimental set up, which allowed controlled mucosal colonisation with indigenous flora and selected bacterial strains after removal of the native flora by antibiotics, and in the straightforward hypothesis and performance of the study; TNBS exerted a direct toxic effect on epithelial cells and disrupted the intestinal barrier, and the effect of *L. casei* on impaired barrier function and bacterial translocation in the TNBS model was examined. Colonisation of bacterial strains, measurement of bacterial translocation, neutrophil tissue influx, and degree of inflammation were evaluated.

The data from this study suggest that *L. casei* administration exerts a protective effect by preventing barrier disruption by TNBS, as translocation of bacteria to mesenteric lymph nodes was significantly reduced in rats colonised with standard rat flora and *L. casei* compared with rats colonised with only standard rat flora. *L. casei* intervention influenced further extension of mucosal injury induced by TNBS, but not the nature of the colonic lesions (transmural lesions were similar in depth compared with TNBS colitis), and resulted in lower myeloid peroxidase activity, a measure of tissue neutrophil infiltration.

The exact mechanisms by which probiotics can influence barrier function remain to be elucidated. It is known that certain lactobacilli adhere to mucosal surfaces, inhibit attachment of pathogenic bacteria, and enhance secretion of mucins. These properties may be instrumental in improving mucosal barrier function and decreasing permeability to macromolecules and toxins. Recently it has been shown that a mixture of probiotic bacteria, in addition to decreasing proinflammatory cytokines—which increase intestinal permeability ( interleukin-1β, tumour necrosis factor α, and IL-8) resulting in mucosal injury by invading immune cells (neutrophils, tissue macrophages, dendritic cells)—reinforce barrier function by secretion of soluble factors that enhance barrier integrity and by regulation of tight junctions. TJ are dynamic structures which represent the major barrier within the paracellular pathway and regulate in a rapid and coordinated way paracellular permeability. Many pathogenic bacteria modulate intestinal permeability by alteration of TJ. Probiotics prevent *Salmonella* induced alteration of the distribution of the TJ protein zonula occcludens 1 and *Salmonella* induced enhanced permeability by increasing transepithelial resistance and decreasing mannitol flux. Maintenance of epithelial barrier function is essential for the preservation of mucosal integrity. Altered TJ structure in ulcerative colitis results in impaired barrier function. Increased permeability in IBD is observed during the active phase of the disease and therefore reinforcement of barrier function, together with their immune modulatory and metabolic properties, may be central in the mechanism of action of probiotic bacteria. Further investigations on how probiotics regulate the TJ complex and influence intestinal permeability are warranted.

Authors’ affiliations

P Giovetti, K M Lammers, F Rizzello, M Campieri, Polyclinic Sant’Orsola, University of Bologna, Department of Internal Medicine and Gastroenterology, Bologna, Italy

Correspondence to: Dr P Giovetti, Polyclinic Sant’Orsola, Department of Internal Medicine and Gastroenterology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy; paolo@med.unibo.it

Conflict of interest: None declared.

REFERENCES


Ulcerative colitis

Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?

P R Gibson, J G Muir

Luminal delivery of phosphatidyl rich phospholipids appears to reduce mucosal inflammatory activity in a high proportion of patients with chronically active ulcerative colitis. The simplicity and apparent safety of this therapeutic approach offers new insights into the importance of the mucus barrier in the pathogenesis and treatment of ulcerative colitis

The treatment of active mucosal inflammation in ulcerative colitis remains challenging. Current therapies have limited efficacy and may be associated with clinically significant adverse effects. There is room for new therapeutic approaches. While nearly all of the existing currently available pharmacological approaches involve attacking various immune and inflammatory pathways in order to facilitate healing, few in the clinician’s current arsenal are directed towards enhancing or protecting the colonic epithelial barrier. Is this situation about to change?

The understanding of the pathogenesis of ulcerative colitis has not considerably progressed over the last decade. The proponents of concepts that the primary abnormalities lie within immune and inflammatory mechanisms have stumbled in attempts to explain the striking features of ulcerative colitis, such as the diffuse nature of the inflammation, its confinement to the mucosal compartment, and its distribution in the large bowel. The alternative concept that primary abnormalities lie within an abnormal epithelial barrier sits more comfortably with these characteristic features of the disease. The barrier has regional differences in structure, composition, and function, which offer simple explanations for, for example, disease distribution. The nature of the inflammatory response in ulcerative colitis—intense polymorph infiltration and predominant antibody mediated T cell activation—is most consistent with exposure of the immune system to large numbers of different “foreign” molecules. Such events might be anticipated in a situation where multiple molecules are able to pass through a deficient epithelial barrier. This is in marked contrast with the situation in Crohn’s disease where the patchy inflammation involving deeper layers of the intestinal wall and draining lymph nodes, together with dominant T cell activation and Th1-type cytokine profile that characterises the response to a limited number of antigens specifically taken up and presented to T cells via MHC class II molecules, has been the basis of much speculation and study. Approaches have ranged from improving the regenerativity of the epithelium (such as the use of growth factors), to trying to enhance energy substrate supply (using butyrate as a substrate), to enhancing the mucous barrier (with trefoil peptides or inhibition of bacterial sulphatases with bismuth). None of these approaches has yet to be promoted from potential to clinical reality because, for example, the theoretical basis was misguided, efficacy was limited, or further development was hindered by funding difficulties and commercial realities. Will further attention to colonic mucus change this situation?

COLONIC MUCUS

The normal colon is lined by a layer of mucus that is more than 100 μm thick. The mucus serves essential functions. It is a lubricant ensuring low friction between moving structures (luminal contents) and the epithelium. This conceptually simple but essential protective function is predominantly the responsibility of surface acting phospholipids.
They form an oligomeric layer that converts the hydrophilic epithelial surface into a hydrophobic one that interfaces with luminal contents. The tight packing together of fatty acid chains provides a good basis for a hydrophobic barrier. Indeed, the regions of the gastrointestinal tract with the most developed hydrophobicity are the stomach and colon, where the potential for injurious insults from luminal factors are the greatest. Most attention in recent years has been paid to other mucous components that subserve complementarily protective functions. Mucins are glycoproteins that function to exclude large molecules (polymers with a molecular weight >20 000) that are not glycoproteins, and to trap other molecules either non-specifically via general “stickiness” or more specifically via carbohydrate structures (lectin binding sites) that may be similar to those on the cell surface. Such trapped matter can be discarded by the constant removal of mucus. It is no surprise then that mucus secretion is increased in the face of threats and this may be mediated, at least in part, by immune events. The mucin environment also supports the presence of other protective proteins and peptides such as secretory IgA, lactoferrin, and trefoil peptides. 

Of all of these components, it has not been clear what is or are the most important from functional, pathogenic, or treatment points of view. Much of the glamour and excitement have surrounded the mucin glycoproteins and other secreted proteins within the mucus. However, recent evidence suggests that the phospholipid component might be a critical factor that can be readily modulated when the mucus barrier is failing.

PHOSPHOLIPIDS

Phospholipids, the major lipid components of mucus, are amphiphilic molecules and contain a polar head group and non-polar hydrocarbon (fatty acid) tails. The major classes of phospholipids include phosphatidylcholine (PC), phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine. In colonic mucus, PC and lysophosphatidylcholine (LPC) are the major species. LPC is an intermediate in the metabolism of PC but is also produced after the hydrolysis of PC by phospholipase A2. Orientation of the lipophilic region of the phospholipid and the nature of the fatty acids characterise the hydrophobicity of the mucus gel layer. The fatty acid tails extend into the lumen to form a “non-wettable” resistant layer. They also extend from the mucosal cell side of the mucus gel. In mucus, the PC species typically contain one saturated (palmitic acid 16:0 or stearic acid 18:0) and one unsaturated (oleic acid 18:1 or linoleic acid 18:2) fatty acid with PC (that is, PC 16:0/18:1 and PC 18:0/18:2). This contrasts with the PC of pulmonary surfactant, dipalmitoylphosphatidylcholine, which contains two saturated fatty acids, palmitic acid (PC 16:0/16:0). The origin of PC in mucus has not been established and more research is required to understand how, when, and where these surface active phospholipids are synthesised, stored, and released. In animal studies, there is some evidence that PC is primarily secreted by the jejunum and ileum, suggesting that PC is delivered to the mucus via the lumen. In these studies, the contribution of PC produced via the colonic epithelium appeared to be minimal. It seems somewhat surprising and highly unlikely that a local source of PC secretion into the mucosal gel layer is not operational. Goblet cells are an obvious site for further investigation. Approaches that have been used to understand the role of surface active phospholipids in the gastric mucosa and as pulmonary surfactants could be readily employed to gain a greater understanding about the production of mucous PC in the colon. A great deal has been learnt by the use of special probes and stains specific for lipophilic areas and choline based phospholipids (see Lichtenberger), and their application to colonic mucus seems warranted.

MUCUS PHOSPHOLIPIDS IN ULCERATIVE COLITIS

As outlined above, mucus is abnormal in patients with ulcerative colitis. There is, however, limited knowledge regarding the phospholipid component of colonic mucus in ulcerative colitis. Recently, quantitatively less PC and LPC were reported in samples taken from the rectal mucosa of patients with ulcerative colitis than from healthy controls and patients with Crohn’s disease. This could be due to reduced production, increased breakdown, or both.

If indeed goblet cells do contribute to the PC content of colonic mucus, they might play more than a passive role in PC depletion of mucus. Goblet cell depletion is a more prominent pathological feature of ulcerative colitis than for Crohn’s colitis. While it might just reflect excessive stimulation of the goblet cells to discharge their mucous, the cells might also be defective in their ability to incorporate PC into the mucus, offering another candidate for the primary abnormality in ulcerative colitis.

Control of PC biosynthesis is a key in the apoptotic programme so that agents that induce apoptosis turn off the biosynthesis of PC. Most epithelial cell death in ulcerative colitis appears to follow an apoptotic pathway. Thus the increased apoptosis that is occurring in the epithelium may deplete the pool of PC by inhibiting its biosynthesis. PC can be destroyed within the epithelium, thereby depleting the pool of PC available for secretion into mucus, or can be destroyed within the mucus itself. Mucosal phospholipase A2 activity is increased in patients with ulcerative colitis or Crohn’s disease, and this activity resides in the epithelium. Protein kinase C, which is involved in several signal transduction pathways linked with inflammatory responses (see Brown and colleagues), activates a PC specific phospholipase C in the plasma membrane with subsequent breakdown of PC. Indeed, colonic mucosa from patients with ulcerative colitis has significantly elevated activity of protein kinase C in the particulate fraction compared with that in normal mucosal samples. Insertion of fluorescent analogues of PC into the plasma membrane of cells followed by activation of protein kinase C with phorbol esters has been used to follow the movement of PC and its metabolites via fluorescent microscopy. A similar approach could be used to gain a greater understanding about the fate of PC in the colonic mucus in ulcerative colitis and in healthy individuals.

Once phospholipids enter the mucus they remain vulnerable to the action of phospholipases, which may be of epithelial origin or derive from mucosa associated bacteria. In the stomach, Helicobacter pylori colonises the mucus layer in part by producing phospholipases A1, A2, and C, and can extract the host phospholipids for its own protective coating. H pylori can also generate high concentrations of ammonium ion that competes with phospholipids for negatively charged glycoprotein binding sites. It is intriguing to speculate about the possible role of a H pylori-like bacterium that might be responsible (in part at least) for the breakdown of the colonic mucous barrier in ulcerative colitis. Large numbers of bacteria are found within the depleted mucus layer of these patients, but whether such bacteria are efficient producers of phospholipases is not known.

The net result of reduced biosynthesis and increased breakdown of phospholipids within the mucosa might be a PC starved system in ulcerative colitis with subsequent depletion of PC available for mucus. Indeed, the observation that plasma phospholipid levels are low in patients with severe ulcerative colitis...
supports such a concept. If this situation were combined with excessive destruction of PC within the mucus layer itself, the ability of PC to offer adequate barrier and lubricant function might be severely compromised. Could correction of phospholipid deficiency of the mucosa and/or mucus be of therapeutic value in ulcerative colitis?

PHOSPHOLIPIDS AS A THERAPY

Phospholipids are readily taken up by mucus, so that the mucous content can be substantially increased by their topical administration. In experimental animals, where there is no abnormality of mucus, topical PC protects the mucosa from luminal insults in the form of acetic acid and trinitrobenzenesulphonic acid, which usually induce colitis. It might be anticipated that the protective and lubricant function of mucus would be considerably enhanced by topical application of PC in a situation such as ulcerative colitis where PC content is reduced. Such a simple concept has recently been evaluated and the results of a randomised controlled trial are reported in this issue of Gut (see page 966). Delivery to the large bowel lumen was achieved by coating of PC enriched phospholipids with Eudragit-S 100. Release of phospholipids from this pH dependent coating was expected to predominantly occur in the terminal ileum and proximal colon, a situation mimicking the putative main source of phospholipids in the colonic mucus. Details of the origin (for example, from soy or egg), and the type of phospholipids and fatty acid species used in this study were not described. Nevertheless, PC was successfully incorporated into rectal mucus confirming that the delivery system works.

In a population of 60 patients with chronically active disease, the efficacy of the PC was astounding; good over a three month treatment period. Compared with a response of 10% in the placebo arm, 90% of the phospholipid treated group responded and 53% were in remission after three months of therapy. No clinically significant side effects were noted. Is this too good to be true?

There were problems with the study design. Despite being described as a single centre study, end points were scored in multiple centres for practical reasons. However, as blinding and randomisation seemed appropriate, heterogeneity of assessment is unlikely to be a significant factor in skewing the results. There were also no data on the time course of efficacy, although a comment in the discussion indicated a slow onset of effect over weeks. The dearth of adverse events in a three month study is somewhat surprising to those used to dealing with randomised controlled drug trials. This suggests laxity in documenting every minor event but again does not detract from the efficacy demonstrated. The placebo treated patients faired badly. A 10% response (and remission) rate is at the lower end of what might be anticipated in most trials, except that patients with chronically active disease, as selected, might have a lower placebo response. The choice of placebo, Eudragit-S 100 coated cellulose, may not have been appropriate. Cellulose would be delivered to the colonic lumen in an identical fashion to that of the phospholipids and, since it is not fermented by colonic bacteria, it might be considered benign and inert. However, cellulose might potentially be abrasive to the mucosa, this being a postulated mechanism by which non-fermentable fibre stimulates epithelial proliferation in fibre starved atrophic colon in otherwise healthy rats. The placebo therefore might have worsened the outcome. On the other hand, there is no evidence that non-fermented fibre is detrimental to the course of ulcerative colitis. Whatever the case, it is still reasonable to say that three months of therapy with PC rich phospholipids delivered to the colonic lumen were convincingly efficacious in inducing remission in patients with chronically active ulcerative colitis.

What about the mechanism of action? It would be precarious to assign this efficacy to the improved hydrophobicity and barrier function of the mucus without confirmatory data. The hydrophobicity of the mucosal layer can be quantified from the “contact angle” after a drop of saline is placed on the mucosal surface. Whether this simple test can be carried out on biopsy specimens or even at colonoscopy is uncertain, but such an assessment in patients with ulcerative colitis seems worthwhile. Alternatively, effects on mucus might only be a minor player in the efficacy. Replenishment of the epithelial pool of PC, with its potential positive effects on improving epithelial health, limiting epithelial destruction, and suppressing its involvement with inflammatory mechanisms, as discussed above, might also be an important mechanism of action.

FUTURE DIRECTIONS

The findings that treatment with PC rich phospholipids permits healing of otherwise difficult to treat ulcerative colitis opens a new approach to the treatment of ulcerative colitis. There is the important need to confirm the results using a more appropriate placebo (perhaps free unsaturated fatty acid such as linoleic acid in place of the cellulose), to determine the appropriate dose, and to define the time course of effect. Additional questions are raised by the complex nature of the phospholipid mixture used. For example, is the effect observed indeed due to the PC component or is the active moiety a minor part of the phospholipid mixture, such as the unsaturated fatty acid component? The question of how this phospholipid mixture is achieving its efficacy, particularly whether it is acting via reinforcement of the mucus, as seems logical, or by other mechanisms, needs to be addressed.

While there has been much previous focus on the mucin glycoproteins, this work shows that more attention needs to be drawn to the less glamorous lipid component, which is not simply playing an inert structural role in the mucus gel layer but rather is a dynamic component of a complex barrier system. The putative efficacy of PC might be enhanced by better distribution using spreading agents. Perhaps liposomes of PC could be used to introduce other therapies such as anti-inflammatory drugs or even antisense RNA that will assist with epithelial healing—two for the price of one! There is also the potential to introduce phospholipids and fatty acid species, such as arachidonic and butyric acids that may have cytoprotective properties. Welcome phospholipids to the cutting edge of ulcerative colitis!

Conflict of interest: None declared.

REFERENCES

6. Gibson PR, Rosella O. Interleukin-8 secretion by colonic crypt cells in vitro: a response to injury that is suppressed by butyrate and enhanced in
Hepatitis C virus

Insulin resistance and steatosis in hepatitis C virus infection

A Zekry, J G McHutchison, A M Diehl

The relationship between hepatitis C virus (HCV), steatosis, and insulin resistance is genotype specific, and steatosis and insulin resistance are closely linked to the progression of liver disease in HCV infected patients

Since the identification of hepatitis C virus (HCV) in the late 1980s, chronic HCV infection has emerged as a complex multifaceted disease with manifestations extending beyond the liver. As such, hepatic steatosis, insulin resistance (IR), and type II diabetes have been observed to occur more frequently in association with HCV infection than other chronic inflammatory liver diseases. A proportion of HCV infected patients with steatosis also exhibit several of the clinical features seen in non-alcoholic steatohepatitis (NASH), questioning the significance of these metabolic disorders in the pathogenesis of HCV related liver disease. Hence, considerable HCV research has recently been directed towards understanding the mechanisms underlying the development of these metabolic manifestations in HCV infected patients and their implications in the progression of liver disease. Several important questions have been examined: are these metabolic disorders in HCV infected patients a result of viral or host factors and, if viral, how do viral proteins interfere with lipid and insulin metabolism? What is the primary event in these patients (steatosis or IR) and what are the implications of steatosis and IR in the pathogenesis of liver disease? Finally, how can we exploit our current knowledge for developing effective therapeutic strategies for HCV infected patients?

In this issue of Gut, Fartoux and colleagues utilise the homeostasis model assessment for IR (HOMA IR) index to study the association between steatosis and IR in patients with chronic HCV infection (see page 1003). In order to examine this association, the authors excluded patients with alternate factors.
known to be associated with the development of steatosis (such as alcohol intake >20 g/day or diabetes). Their findings confirm earlier observations\(^\text{11}\) that differing and genotype specific mechanisms characterise the development of hepatic steatosis in HCV infected patients. Accordingly, steatosis in genotype 3 infected patients is primarily viral mediated (cytopathic) whereas host factors, principally those associated with IR and its clinical attributes, are responsible for the development of steatosis in the genotype 1 infected patient.

### DIRECT STEATOCENIC EFFECT OF HCV

Evidence for a HCV genotype 3 specific steatogenic effect has come from several clinical observations (table 1).\(^\text{16–18}\) Furthermore, this direct steatogenic effect of HCV is highly reproducible in transgenic mice and cell culture models of hepatitis C, in which overexpression of viral protein (such as core and NS5A) has been shown to induce accumulation of intracytoplasmic triglyceride rich droplets.\(^\text{9}\)

There are several identified mechanisms whereby HCV may alter lipid metabolism. Firstly, HCV core protein has been shown to directly inhibit the function of microsomal triglyceride transfer protein, a major regulator of hepatic assembly, and secretion of nascent triglyceride rich very low density lipoproteins (VLDL). The latter effect impairs the ability of hepatocytes to assemble and secrete VLDL.\(^\text{10,11}\) Secondly, HCV core protein has been observed to induce mitochondrial injury resulting in oxidative stress. Oxidative stress perturbs lipid peroxidation, thereby contributing to the development of steatosis.\(^\text{12–14}\) Finally, microarray studies have illustrated the ability of HCV (in particular genotype 3) to induce transcription of several genes involved in lipid metabolism in the liver.\(^\text{15,16}\) Among these is stearoyl coenzyme A desaturase 4 (SCD4), a rate limiting enzyme in the synthesis of monounsaturated fats.\(^\text{17}\) Reduced expression of SCD4 in livers of o//o mice has been shown to significantly ameliorate hepatic steatosis.\(^\text{17}\)

### INSULIN RESISTANCE AND STEATOSIS IN HCV INFECTED PATIENTS

Steatosis in patients with genotype 1 infection is increasingly recognised as a component of the metabolic syndrome, a condition invariably associated with IR. In support, host factors such as age, body mass index (BMI), and central obesity, have been shown to correlate with the development of steatosis in genotype 1 infected patients (but not genotype 3).\(^\text{18}\) Fartoux and colleagues\(^\text{2}\) have further demonstrated that HOMA IR was the only risk factor independently associated with the development of steatosis in genotype 1 infected patients (p = 0.001). Moreover, the degree of steatosis was significantly predictive of HOMA IR (p = 0.004).

There are several uncertainties regarding the cascade of events leading to the development of IR and steatosis in HCV infected patients with features of the metabolic syndrome. As such, whether IR or steatosis is the primary or secondary event in these patients is unclear.

Overall, there are sufficient clinical and experimental data indicating that excess fat can perpetuate IR: large epidemiological studies reveal that the risk of IR rises as body fat content (determined by BMI), and central obesity, have been shown to correlate with the development of steatosis in genotype 1 infected patients (p = 0.001). Moreover, the degree of steatosis was significantly predictive of HOMA IR (p = 0.004).

There are several uncertainties regarding the cascade of events leading to the development of IR and steatosis in HCV infected patients with features of the metabolic syndrome. As such, whether IR or steatosis is the primary or secondary event in these patients is unclear.

### HCV AND INSULIN RESISTANCE

Several studies (including that of Fartoux and colleagues\(^\text{2}\)) evaluating IR in patients with chronic HCV infection have found that the development of IR can occur early in the course of the disease. This effect appears to be independent of body weight, stage of liver disease, and presence or absence of overt diabetes.\(^\text{10–12}\) There are other clinical observations supporting a “fat independent” mechanism in the development of IR in HCV infected patients. Firstly, Fartoux and colleagues\(^\text{2}\) and others\(^\text{24}\) have observed that patients infected with HCV genotype 3 have more extensive hepatic steatosis but a lower incidence of IR.\(^\text{22}\) This observation supports a genotype specific mechanism underlying IR in HCV infected patients.\(^\text{22}\) Secondly, two studies demonstrated that clearance of HCV with antiviral therapy resulted in restoration of insulin sensitivity and euglycaemia.\(^\text{14,15}\) Finally, the extent of IR has been shown to correlate with the
Figure 1. Molecules that are likely to be involved in mediating insulin resistance (IR) in hepatitis C virus (HCV) infection. Tumour necrosis factor α (TNF-α) is increased in the serum and liver of HCV infected patients. TNF induces IR by decreasing the tyrosine kinase activity of insulin receptor substrate 1 (IRS-1).7 Treatment of HCV core transgenic mice with anti-TNF-α has been shown to restore insulin sensitivity. High levels of suppressor of cytokine signalling 3 (SOCS3) have been reported to mediate inhibition of this region.38 These observations are relevant as HCV is recognised as influencing the expression of SOCS protein in obese animals.39 The PEPCK gene itself is a target for leptin (also increased in HCV infection) mediated regulation of gluconeogenesis in the liver.40 In agreement with previous observation is quite important in light of recent data demonstrating direct involvement of SOC1 and SOC3 in regulating expression of SREBP-1c in the livers of obese animals.41 These animal models, overexpression of SOC1 and SOC3 proteins has been shown to enhance SREBP-1c promoter activity by attenuating signal transducer and activator of transcription 3 (STAT-3) mediated inhibition of this region.16 The net effect in these animals was development of systemic IR and hepatic steatosis. Conversely, inhibiting expression of SOCS proteins in obese animals normalised levels of SREBP-1 and improved insulin sensitivity and hepatic steatosis. Consistent with these data, hepatic STAT-3 signalling has recently been shown to be essential for normal glucose homeostasis and insulin sensitivity.42 These observations are relevant as HCV is recognised as influencing the activity of STAT-3. It is therefore intriguing to speculate that STAT-3 may be one of the key molecules involved in HCV mediated IR (fig 1).

ROLE OF CYTOKINES
Tumour necrosis factor α (TNF-α) levels are elevated in the liver and serum of patients with chronic HCV infection. TNF-α plays an important role in the development of IR through interfering with insulin signalling.43 In IR HCV core transgenic mice, treatment with anti-TNF-α restored insulin sensitivity, thus supporting the notion that TNF-α is a major factor for the development of IR in HCV infection.44

ROLE OF STEATOSIS AND INSULIN RESISTANCE IN PROGRESSION OF HCV LIVER DISEASE
In agreement with previous reports,4 7 41 Fartoux and colleagues observed an association between steatosis and severity of fibrosis, irrespective of HCV genotype. While insulin levels were predictive of fibrosis in their univariate analysis, subsequent multivariate analysis confirmed steatosis, but not insulin levels, to be independently associated with fibrosis (p = 0.02).

Thus two key questions arise: is fat per se fibrogenic and what is the role of insulin in the fibrotic process? Steatosis is associated with increased production of reactive oxygen species which initiate lipid peroxidation, resulting in hepatic stellate cell activation.45 However, in NASH, disease progression is recognised as being slower than that observed in patients with HCV infection and steatosis. Thus it is likely that the coexistence of HCV and steatosis aggravates and accelerates the injury induced by each alone. In this setting, hepatic inflammation induced by the host response, together with the increased production of several proinflammatory and profibrotic cytokines, provide the substrate for the “second hit” in the steatotic liver. Also, the blood of the virus itself to induce oxidative stress and promote lipid peroxidation may further aggravate the pathogenic process induced by steatosis. Consider also that fat may render HCV infected liver more vulnerable to injury. Livers with steatosis are more sensitive to TNF-α mediated inflammation and liver injury.46 Moreover, in HCV livers with steatosis, apoptosis activity has been noted to be increased compared with infected livers without steatosis.47

While Fartoux and colleagues could not find a direct association between IR and fibrosis, others have.48 49 The authors do concede that insulin plays a significant role in the development of fibrosis via a mechanism involving steatosis. In this regard, steatosis promotes cellular IR which, in turn, induces compensatory hyperinsulinaemia. Hyperinsulinaemia has been shown to directly stimulate hepatic stellate cell proliferation and increase expression of connective tissue growth factor, a key factor in the progression of fibrosis.46 Collectively, the data implicate both steatosis and IR in liver disease progression in HCV infected patients.

CONCLUSIONS
Our knowledge of the mechanisms and significance of steatosis and IR in patients with chronic HCV infection has advanced. The work by Fartoux and colleagues adds to the growing evidence that the relationship between HCV, steatosis, and IR is genotype specific and that steatosis and IR are closely linked to the progression of liver disease in HCV infected patients. As
such, we need to clarify the molecular pathways involved in mediating these inter-relations. In light of our current knowledge of the implications of steatosis and IR in liver disease, the importance of lifestyle changes (such as weight loss) need to be an emphasised in treating HCV infected patients. Similarly, new therapeutic approaches exploiting the interaction between HCV and lipid metabolism are eagerly awaited.

ACKNOWLEDGEMENTS

This work was supported by a grant from NIH, Z01DK53572.

doi: 10.1136/gut.2004.059873

Authors’ affiliations

A Zekry, J G McHutchison, A M Diehl, Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Centre, Durham, North Carolina, USA

Correspondence to: Dr A M Diehl, Division of Gastroenterology, Duke University, Snydeman Building, GSRB-1, Suite 1073, Box 1270, Durham, NC 27710, USA; diehl004@mc.duke.edu

Conflict of interest: None declared.

REFERENCES